Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14α-hydroxy-4-androstene-3,6,17-trione is a **synthetic steroidal compound** with reported **aromatase inhibitory activity**, making it potentially useful as an antitumor agent.[1] Aromatase is an enzyme responsible for converting anrogens to estrogens; inhibition of this enzyme can reduce estrogen biosynthesis, which is a target in certain hormone-dependent cancers. This compound was developed via selective oxidation of 6-β,14-α-dihydroxy-4-androstene-3,17-dione, and displays a molecular formula of C19H24O4 and a molecular weight of 316.[1][6] It is classified as a triketone and has the appearance of a white powder. The mechanism of action is analogous to that of **irreversible aromatase inhibitors**, which permanently inactivate the enzyme and thereby reduce estrogen production.[1] There is no evidence it is approved or marketed as a pharmaceutical or dietary supplement, and no information identifying any brand or code names associated with this chemical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 14α-hydroxy-4-androstene-3,6,17-trione.